Replicate Bioscience has entered into a multi-year research collaboration with Novo Nordisk A/S to develop self-replicating RNA (srRNA) therapies for obesity, type 2 diabetes and other cardiometabolic diseases. The deal combines Novo Nordisk’s expertise in metabolic disorders with Replicate’s proprietary srRNA platform, designed to enable scalable and durable protein expression.
